281 related articles for article (PubMed ID: 23457302)
1. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Xu J; Walls CD; Chen L; Zhang S; Zhang R; Wu L; Wang L; Liu S; Zhang ZY
J Biol Chem; 2013 Apr; 288(15):10472-82. PubMed ID: 23457302
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
[TBL] [Abstract][Full Text] [Related]
4. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
5. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
6. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
Stewart RA; Sanda T; Widlund HR; Zhu S; Swanson KD; Hurley AD; Bentires-Alj M; Fisher DE; Kontaridis MI; Look AT; Neel BG
Dev Cell; 2010 May; 18(5):750-62. PubMed ID: 20493809
[TBL] [Abstract][Full Text] [Related]
7. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
8. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
10. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
11. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
[TBL] [Abstract][Full Text] [Related]
12. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
Lorca R; Pannone L; Cuesta-Llavona E; Bocchinfuso G; Rodríguez-Reguero J; Carpentieri G; Hernando I; Flex E; Tartaglia M; Coto E; Gómez J; Martinelli S
Clin Genet; 2021 Mar; 99(3):457-461. PubMed ID: 33354767
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
14. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
Martinelli S; Torreri P; Tinti M; Stella L; Bocchinfuso G; Flex E; Grottesi A; Ceccarini M; Palleschi A; Cesareni G; Castagnoli L; Petrucci TC; Gelb BD; Tartaglia M
Hum Mol Genet; 2008 Jul; 17(13):2018-29. PubMed ID: 18372317
[TBL] [Abstract][Full Text] [Related]
15. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
[TBL] [Abstract][Full Text] [Related]
16. [The Biological Function of SHP2 in Human Disease].
Li SM
Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
[TBL] [Abstract][Full Text] [Related]
17. Phosphoproteomics-mediated identification of Fer kinase as a target of mutant Shp2 in Noonan and LEOPARD syndrome.
Paardekooper Overman J; Preisinger C; Prummel K; Bonetti M; Giansanti P; Heck A; den Hertog J
PLoS One; 2014; 9(9):e106682. PubMed ID: 25184253
[TBL] [Abstract][Full Text] [Related]
18. Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds.
Guo W; Xu Q
J Pharmacol Sci; 2020 Nov; 144(3):139-146. PubMed ID: 32921395
[TBL] [Abstract][Full Text] [Related]
19. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?
Lauriol J; Kontaridis MI
Trends Cardiovasc Med; 2011 May; 21(4):97-104. PubMed ID: 22681964
[TBL] [Abstract][Full Text] [Related]
20. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
